Physiomics Plc (PYC) - Total Liabilities

Latest as of December 2025: GBX165.00K GBX ≈ $20.08 USD

Based on the latest financial reports, Physiomics Plc (PYC) has total liabilities worth GBX165.00K GBX (≈ $20.08 USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Physiomics Plc - Total Liabilities Trend (2001–2025)

This chart illustrates how Physiomics Plc's total liabilities have evolved over time, based on quarterly financial data. See Physiomics Plc (PYC) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Physiomics Plc Competitors by Total Liabilities

The table below lists competitors of Physiomics Plc ranked by their total liabilities.

Company Country Total Liabilities
World Chess PLC
LSE:CHSS
UK GBX2.97 Million
Anemoi International Ltd
LSE:AMOI
UK GBX220.87K
Chordate Medical Holding AB
ST:CMH
Sweden Skr4.14 Million
Alina Holdings PLC
LSE:ALNA
UK GBX787.39K
WICKET GAMING AB
F:7Q4
Germany €35.31 Million
Sonder Holdings Inc
NASDAQ:SOND
USA $1.49 Billion
Hsin Yung Chien Co Ltd
TW:2114
Taiwan NT$597.24 Million

Liability Composition Analysis (2001–2025)

This chart breaks down Physiomics Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PYC market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.30 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.42 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.30 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Physiomics Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Physiomics Plc (2001–2025)

The table below shows the annual total liabilities of Physiomics Plc from 2001 to 2025.

Year Total Liabilities Change
2025-06-30 GBX199.85K
≈ $24.32
+42.68%
2024-06-30 GBX140.08K
≈ $17.04
-1.82%
2023-06-30 GBX142.67K
≈ $17.36
+1.47%
2022-06-30 GBX140.61K
≈ $17.11
-10.76%
2021-06-30 GBX157.57K
≈ $19.17
+19.81%
2020-06-30 GBX131.52K
≈ $16.00
+52.27%
2019-06-30 GBX86.37K
≈ $10.51
-32.63%
2018-06-30 GBX128.21K
≈ $15.60
+47.50%
2017-06-30 GBX86.92K
≈ $10.58
-12.34%
2016-06-30 GBX99.16K
≈ $12.06
+86.22%
2015-06-30 GBX53.25K
≈ $6.48
-50.56%
2014-06-30 GBX107.71K
≈ $13.10
-13.59%
2013-06-30 GBX124.64K
≈ $15.17
+18.11%
2012-06-30 GBX105.53K
≈ $12.84
-5.78%
2011-06-30 GBX112.00K
≈ $13.63
-17.04%
2010-06-30 GBX135.00K
≈ $16.43
-62.50%
2009-06-30 GBX360.00K
≈ $43.80
-23.08%
2008-06-30 GBX468.00K
≈ $56.94
+129.41%
2007-06-30 GBX204.00K
≈ $24.82
-3.77%
2006-06-30 GBX212.00K
≈ $25.79
+85.96%
2005-06-30 GBX114.00K
≈ $13.87
-74.50%
2004-06-30 GBX447.00K
≈ $54.39
+114.90%
2003-06-30 GBX208.00K
≈ $25.31
+2211.11%
2001-06-30 GBX9.00K
≈ $1.10
--

About Physiomics Plc

LSE:PYC UK Biotechnology
Market Cap
$28.95K
GBX237.93 Million GBX
Market Cap Rank
#31493 Global
#1250 in UK
Share Price
GBX0.53
Change (1 day)
+10.53%
52-Week Range
GBX0.27 - GBX0.70
All Time High
GBX17.13
About

Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour pred… Read more